Persistent Depressive Disorder Quality Control & Assurance 2 — Questions and Answers
Question 1: Which validated tool is most commonly used to monitor treatment response and symptom severity over time in patients with Persistent Depressive Disorder?
- Beck Anxiety Inventory (BAI)
- Patient Health Questionnaire-9 (PHQ-9) (Correct answer)
- CAGE Questionnaire
- Positive and Negative Syndrome Scale (PANSS)
Correct answer: Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is widely used in clinical settings to track depressive symptom severity and treatment response in PDD.
Question 2: A quality assurance audit finds that clinicians are not documenting functional impairment in PDD cases. Why is this a critical gap?
- Functional impairment is not required for PDD diagnosis
- DSM-5 requires clinically significant distress or functional impairment as a diagnostic criterion (Correct answer)
- Documentation of impairment is only needed for insurance billing
- Functional status is only relevant for inpatient settings
Correct answer: DSM-5 requires clinically significant distress or functional impairment as a diagnostic criterion
DSM-5 requires that PDD symptoms cause clinically significant distress or functional impairment, making its documentation essential for diagnostic validity.
Question 3: What is the minimum symptom duration that must be documented to meet quality standards for a valid PDD diagnosis in adults?
- 6 months
- 1 year
- 2 years (Correct answer)
- 5 years
Correct answer: 2 years
PDD requires depressed mood for at least 2 years in adults, and failure to document this duration is a quality error.
Question 4: A clinic implements measurement-based care (MBC) for PDD patients. What is the primary quality benefit of this approach?
- It reduces the need for diagnostic interviews
- It allows treatment adjustments based on objective, tracked symptom data (Correct answer)
- It eliminates the need for supervision
- It replaces the requirement for treatment planning
Correct answer: It allows treatment adjustments based on objective, tracked symptom data
MBC uses standardized assessments at each visit to inform data-driven treatment decisions and improve outcomes in PDD.
Question 5: According to quality standards, how long should a clinician wait before evaluating the adequacy of an antidepressant trial for PDD?
- 1–2 weeks
- 2–4 weeks
- 4–8 weeks at therapeutic dose (Correct answer)
- 6 months
Correct answer: 4–8 weeks at therapeutic dose
An adequate antidepressant trial typically requires 4–8 weeks at therapeutic dose before efficacy can be assessed.
Question 6: Which quality indicator best reflects adherence to evidence-based psychotherapy standards for PDD?
- Number of sessions completed regardless of content
- Use of structured, manualized therapies such as CBT or CBASP (Correct answer)
- Therapist's years of experience alone
- Patient satisfaction scores only
Correct answer: Use of structured, manualized therapies such as CBT or CBASP
Evidence-based care requires the use of structured, manualized therapies like CBT or Cognitive Behavioral Analysis System of Psychotherapy (CBASP) for PDD.
Question 7: A PDD patient has not shown improvement after 12 weeks of first-line therapy. What does quality assurance recommend?
- Continue the same treatment indefinitely
- Discharge the patient
- Conduct a formal treatment review and consider augmentation or switching strategies (Correct answer)
- Refer solely to a peer support group
Correct answer: Conduct a formal treatment review and consider augmentation or switching strategies
Quality standards require a formal treatment review and consideration of alternative strategies when a patient fails to respond within an adequate trial period.
Persistent Depressive Disorder Quality Control & Assurance 2
Which validated tool is most commonly used to monitor treatment response and symptom severity over time in patients with Persistent Depressive Disorder?